Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This study is designed as a 2-part study, with Part 1 being open-label to best determine the
appropriate dose levels to use in Part 2, which has a randomized, double-blind, placebo
controlled design. The study aims to assess the safety and tolerability of BGS649, and
determine whether or not BGS649 is able to normalize testosterone levels and improve insulin
sensitivity in obese, hypogonadotropic hypogonadal (OHH) men